Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
- Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. doi: 10.3390/ph12020063.
Affiliations
- 1. Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal. [email protected].
- 2. CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal. [email protected].
- 3. Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal. [email protected].
- 4. CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal. [email protected].
PMID: 31010063
DOI: 10.3390/ph12020063
Abstract
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline Antibacterial. It can be used in community-acquired pneumonia and in acute Bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection Antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria.
Keywords
FDA approved; Omadacycline; aminomethylcycline; antibacterial; protein synthesis inhibitor; tetracycline.
Products